Evaluating Immunome: Insights From 4 Financial Analysts
Evaluating Immunome: Insights From 4 Financial Analysts
評估免疫組：來自4位金融分析師的見解
In the preceding three months, 4 analysts have released ratings for Immunome (NASDAQ:IMNM), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月裏，有4位分析師發佈了針對Immunome (NASDAQ:IMNM)的評級，展示了從看好到看淡的廣泛觀點。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級概況，突出了過去30天內情緒的變化，並將其與之前的月份進行了比較。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.75, a high estimate of $35.00, and a low estimate of $24.00. This current average reflects an increase of 10.19% from the previous average price target of $27.00.
分析師的12個月價格目標提供的見解顯示，平均目標爲29.75美元，最高估值爲35.00美元，最低估值爲24.00美元。與之前的平均目標價格27.00美元相比，當前平均目標反映了10.19%的增長。
Understanding Analyst Ratings: A Comprehensive Breakdown
分析師評級：全面解析
A comprehensive examination of how financial experts perceive Immunome...
從最近分析師行動中...
登入免費觀看全文
登入/註冊